← Blog
Federal Jul 6, 2026 · 5 min read

The DEA Telehealth Cliff: What Happens on December 31, 2026

The fourth extension of COVID-era DEA prescribing flexibilities expires December 31, 2026. No permanent rule has been finalized. Here is what that means for physicians who prescribe controlled substances via telehealth.

On December 31, 2026, the fourth temporary extension of COVID-era DEA telemedicine prescribing flexibilities expires. Under these flexibilities, DEA-registered physicians can prescribe Schedule II through V controlled substances via audio-video telehealth without a prior in-person visit. If the extension lapses without a replacement — either a fifth extension or a finalized permanent rule — the Ryan Haight Act's in-person requirement reinstates immediately.

What the Ryan Haight Act requires without the extension

The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 generally prohibits prescribing controlled substances via the internet unless the practitioner has conducted at least one in-person medical evaluation of the patient. Without the DEA extension, this requirement applies to telehealth prescribing. Physicians who have been prescribing controlled substances to telehealth patients without a prior in-person visit would need to either conduct an in-person visit or transfer care before January 1, 2027.

Source · Ryan Haight Act · 21 U.S.C. § 829(e) · DEA Fourth Temporary Extension · Federal Register Vol. 90 No. 1 (2026)

What is the proposed permanent rule?

The DEA proposed a permanent rule — Special Registrations for Telemedicine — in January 2025. It would create three pathways: a practitioner special registration, a platform registration, and a limited state telemedicine registration. The rule received over 6,000 public comments. As of July 2026, it has not been finalized. The direction of the current administration on this rule is unclear.

If December 31 passes without a fifth extension or a finalized permanent rule, the Ryan Haight in-person requirement reinstates immediately.

What physicians should do now

Review your patient panel for patients receiving controlled substances exclusively via telehealth, without any prior in-person evaluation. For each, consider whether an in-person visit before December 31 is feasible, whether the patient can be transferred to an in-person practice, or whether an audio-only exception applies (buprenorphine for OUD only, under the current extension). Do not wait until Q4 — in-person appointment availability tightens significantly toward year-end.

State-specific rules still apply

Even under the federal extension, some states impose stricter requirements. Florida prohibits Schedule II prescribing via telehealth except for hospice and nursing home patients. New York has issued its own final rule on telehealth CS prescribing that imposes additional in-person examination requirements for new patients. Always check state law alongside federal rules.

Sources
DEA · 21 U.S.C. § 829(e) · Federal Register Vol. 88 No. 43 · Federal Register Vol. 90 No. 1 · CCHP Fall 2025 Report
This post cites primary sources and was reviewed before publication. Not for legal or clinical decision-making. For compliance decisions with regulatory consequences, confirm requirements directly with your state board.
Related posts
Federal

DEA Telehealth Prescribing Flexibilities Extended — Permanent Rule Still Pending

May 15, 2026 · 4 min
Federal

DEA Permanent Telehealth Prescribing Rule — Final Rulemaking Expected 2026

May 13, 2026 · 5 min
Federal

CONNECT for Health Act: What It Would Change for Telehealth Physicians

Jul 6, 2026 · 4 min
Get started · 14-day free trial

A roster, a calendar, and an editor — for every state you practice.

No credit card. Cancel anytime.